Obach RS, Reed-Hagen AE. Measurement of Michaelis constants for cytochrome
P450-mediated biotransformation reactions using a substrate depletion approach.
Drug Metab Dispos 2002;30:831–837.
Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine
oxidationin vitrois catalysed by CYP2 D6. Br J Clin Pharmacol 1996;41:149–156.
Overby LH, Buckpitt AR, Lawton MP, Atta-Asafo-Adjei E, Schulze J, Philpot RM.
Characterization of flavin-containing monooxygenase 5 (FMO5) cloned from
human and guinea pig: evidence that the unique catalytic properties of FMO5 are
not confined to the rabbit ortholog. Arch Biochem Biophys 1995;317:
275–284.
Overby LH, Carver GC, Philpot RM. Quantitation and kinetic properties of hepatic
microsomal and recombinant flavin-containing monooxygenases 3 and 5 from
humans. Chem Biol Interact 1997;106:29–45.
Pacifici G. Inhibition of human liver and duodenum sulfotransferases by drugs and
dietary chemicals: a review of the literature. Int J Clin Pharmacol Ther 2004;42:
488–495.
PHARMACIA,UPJOHN. 2004. Drug label approved on 07/21/2005 for
CAMPTOSAR, NDA no. 020571, U.S. Food and Drug Administration. Avaliable
at.http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from
recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica
2004;34:151–178.
Remmel RP, Burchell B. Validation and use of cloned, expressed human drug-
metabolizing enzymes in heterologous cells for analysis of drug metabolism and
drug-drug interactions. Biochem Pharmacol 1993;46:559–566.
Ring BJ, Wrighton SA. Industrial Viewpoint: Application ofIn VitroDrug Metabolism
in Various Phases of Drug Development. Philidelphia:Lippincott Williams &
Wilkins;2000.
Rios GR, Tephly TR. Inhibition and active sites of UDP-glucuronosyltransferases 2B7
and 1 A1. Drug Metab Dispos 2002;30:1364–1367.
Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge
the gap between cDNA-expressed cytochromes P450 and native human liver
microsomes. Biochem Pharmacol 1999;57:465–480.
Rowland M, Matin S. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm
1973;1:553–567.
Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to
functions. Annu Rev Pharmacol Toxicol 1998;38:257–288.
Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current
progress on esterases: from molecular structure to function. Drug Metab Dispos
2002;30:488–493.
Schneider H, Glatt H. Sulpho-conjugation of ethanol in humans in vivoand by
individual sulphotransferase formsin vitro. Biochem J 2004;383:543–549.
Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev
Neurosci 1999;22:197–217.
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual
variations in human liver cytochrome P-450 enzymes involved in the oxidation of
508 REACTION PHENOTYPING